Ivantis Inc. Expanded Its Presence In The Novel Drugs And Devices To Lower Intraocular Pressure Market With The Launch Of Hydrus Microstent: A Device Used In Minimally Invasive Glaucoma Surgery
Increasing approval of drugs and devices associated with the treatment of glaucoma from regulatory bodies is projected to foster the growth of the novel drugs and devices to lower intraocular pressure market. For instance, in May 2019, Ivantis Inc. received an approval from the U.S. Food and Drug Administration (FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is developed to lower eye pressure in patients with open-angle glaucoma. North America is expected to lead the global novel drugs and devices to lower intraocular pressure market over the forecast period due to increasing FDA approval for drug launch. For instance, in September 2018, Sun Pharmaceuticals Industries Ltd. received approval from U.S. FDA for Xelpros (latanoprost ophthalmic emulsion) for the treatment of glaucoma. It reduces the elevated intraocular pressure in the eye and has been designed with the help of Swollen Micelle Microemulsion technology. In March 2020, Allerg